Verdence Capital Advisors Increases Stake in Johnson & Johnson

2 min read | November 10, 2024 03:21 AM PST | By Team Kalkine Media

Headlines

  • Verdence Capital Advisors boosts its holdings in Johnson & Johnson, signaling continued interest in the healthcare leader.
  • Other institutional investors strengthen their positions in JNJ, highlighting broad support.
  • Johnson & Johnson maintains appeal with strategic investments from notable asset managers.

Verdence Capital Advisors LLC recently expanded its stake in Johnson & Johnson (NYSE:JNJ), increasing its holdings by over 22% during the third quarter. According to the latest SEC filing, Verdence Capital Advisors now owns more than 45,000 shares in Johnson & Johnson after adding an additional 8,480 shares this period. This move reflects Verdence’s confidence in Johnson & Johnson’s ongoing growth prospects within the healthcare sector.

Alongside Verdence, several other institutional investors and hedge funds have also adjusted their positions in Johnson & Johnson. Meridian Financial Partners LLC recently acquired a new position in the company, reflecting its interest in JNJ’s long-term potential. Meanwhile, LMCG Investments LLC increased its investment in Johnson & Johnson by over 30% in the third quarter, bringing its total share count to over 87,000. LMCG’s decision aligns with a broader trend of institutional confidence in JNJ’s performance.

NTV Asset Management LLC and Cooper Haims Advisors LLC also expanded their stakes in Johnson & Johnson in recent quarters. NTV Asset Management increased its holdings by a small margin, while Cooper Haims raised its position by over 6%, contributing to the wide base of institutional backing. Similarly, Trajan Wealth LLC boosted its shares in Johnson & Johnson by more than 11% during the third quarter, further highlighting JNJ’s role in diversified portfolios.

With approximately 70% of Johnson & Johnson shares owned by institutional investors, the company continues to attract significant attention from the financial sector. The steady influx of institutional support reinforces Johnson & Johnson’s standing as a key player in healthcare, appealing to investors who are optimistic about its growth trajectory and stability in the industry.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next